- Home
- LPRO vs IMRX Comparison
LPRO vs IMRX Comparison
Compare LPRO & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- IMRX
- Stock Information
- Founded
- LPRO 2000
- IMRX 2008
- Country
- LPRO United States
- IMRX United States
- Employees
- LPRO N/A
- IMRX N/A
- Industry
- LPRO Finance: Consumer Services
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- IMRX Health Care
- Exchange
- LPRO Nasdaq
- IMRX Nasdaq
- Market Cap
- LPRO 252.9M
- IMRX 232.9M
- IPO Year
- LPRO N/A
- IMRX 2021
- Fundamental
- Price
- LPRO $1.88
- IMRX $7.40
- Analyst Decision
- LPRO Buy
- IMRX Strong Buy
- Analyst Count
- LPRO 7
- IMRX 5
- Target Price
- LPRO $2.83
- IMRX $17.20
- AVG Volume (30 Days)
- LPRO 772.4K
- IMRX 1.2M
- Earning Date
- LPRO 11-06-2025
- IMRX 11-12-2025
- Dividend Yield
- LPRO N/A
- IMRX N/A
- EPS Growth
- LPRO N/A
- IMRX N/A
- EPS
- LPRO N/A
- IMRX N/A
- Revenue
- LPRO $16,948,000.00
- IMRX N/A
- Revenue This Year
- LPRO $306.78
- IMRX N/A
- Revenue Next Year
- LPRO $11.69
- IMRX N/A
- P/E Ratio
- LPRO N/A
- IMRX N/A
- Revenue Growth
- LPRO N/A
- IMRX N/A
- 52 Week Low
- LPRO $0.70
- IMRX $1.10
- 52 Week High
- LPRO $6.75
- IMRX $10.08
- Technical
- Relative Strength Index (RSI)
- LPRO 57.66
- IMRX 61.63
- Support Level
- LPRO $1.45
- IMRX $6.62
- Resistance Level
- LPRO $1.67
- IMRX $7.50
- Average True Range (ATR)
- LPRO 0.14
- IMRX 0.62
- MACD
- LPRO 0.04
- IMRX 0.08
- Stochastic Oscillator
- LPRO 97.49
- IMRX 87.50
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.